BioMarin appoints Erin Burkhart as Chief Accounting Officer

BIOMARIN PHARMACEUTICAL INC

Burkhart named Group VP, CAO effective May 2, 2022; succeeds Brian Mueller who remains CFO and principal financial officer.
Burkhart joins from Eli Lilly where she held senior roles; CPA with public accounting background at Arthur Andersen and Deloitte.
Compensation includes $400K salary, 45% cash incentive target, $250K sign-on bonus, $250K relocation bonus, and $1.5M equity awards (RSUs + options).
Equity grants under 2017 Equity Incentive Plan; RSUs vest 25% annually, options vest monthly over 4 years with 1-year cliff.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erin Burkhart

Group Vice President, Chief Accounting Officer

BMRN · BIOMARIN PHARMACEUTICAL INC

Effective: 2022-05-02
Filed: May 5, 2022, 7:59 PM ET

On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erin Burkhart was appointed as Group Vice President, Chief Accounting Officer at BIOMARIN PHARMACEUTICAL INC.

Action: appointed
Role: Group Vice President, Chief Accounting Officer

Exact text from the filing

On May 05, 2022., BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) announced the appointment of Erin Burkhart as BioMarin’s Group Vice President, Chief Accounting Officer, effective May 2, 2022.

View on SEC.gov

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-22-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.